<DOC>
	<DOCNO>NCT02405221</DOCNO>
	<brief_summary>This study look dose TA-CIN/GPI-0100 vaccine safe effective patient history HPV16 associate cervical cancer .</brief_summary>
	<brief_title>Clinical Trial Safety Feasibility TA-CIN Vaccine Combination With GPI-0100 Adjuvant Patients With History HPV16 Associated Cervical Cancer</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<criteria>1 . Patients HPV16 related stage IB1IV cervical cancer complete definitive treatment within 3 year 2 . Patients evidence disease recurrence 3 . Age â‰¥ 18 year 4 . ECOG Performance Status 0 1 5 . Adequate organ function define studyspecified laboratory test 6 . Must use acceptable form birth control study 28 day final dose study drug 7 . Signed informed consent form 8 . Willing able comply study procedures 1 . Currently history certain studyspecified heart , liver , kidney , lung , neurological , immune medical condition 2 . Systemically active steroid use 3 . Prior HPV vaccination 4 . Had surgery , chemotherapy , radiation therapy within 28 day prior receive study drug 5 . Another investigational product within 28 day prior receive study drug 6 . Active chronic HIV , HBV , HCV infection 7 . Pregnant lactating</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>